Navigation Links
New licensing agreement to maximize AIDS drug development

Longtime collaborators CONRAD and the Biosyn Division of Cellegy Pharmaceuticals, Inc. today announced a non-exclusive licensing agreement to research and develop Biosyn-patented microbicides for the prevention of HIV and other sexually transmitted diseases.

The three microbicides covered under the agreement are in various stages of development and work under different mechanisms of action. They include: Savvy, which is currently in Phase III clinical trials in the U.S. and Africa; UC781 which is in expanded Phase II trials in the U.S and Thailand and Cyanovirin-N which is in preclinical testing. Henry Gabelnick, Ph.D., executive director of CONRAD says, "This agreement is great news for everyone interested in developing an effective microbicide. The more partnerships we have like this one, the better our potential is for getting an effective product ready for distribution."

"I am delighted for our two organizations to enter into this agreement. We have collaborated for many years on all aspects of our microbicide development programs, and we have a deep respect for each other's knowledge and expertise. With CONRAD, we feel we have a capable and experienced partner to work with us toward approval of these critically important products," said Anne-Marie Corner, Senior Vice President of Cellegy Pharmaceuticals.Currently, the highest rates of infection in women are in sub-Saharan Africa and rates are increasing in women in South and Southeast Asia.

CONRAD has been involved in the research of nearly every microbicide currently in clinical trials. They are currently managing a second Phase III trial of a microbicide called Ushercell in Uganda and South Africa, Benin, Burkina Faso and two centers in India. The trials will evaluate Ushercell for the prevention of HIV infection among 2,574 adult women at high risk of acquiring HIV. This study will also assess incidence of genital gonorrhea and chlamydia.

CONRAD is a cooperating agen cy of USAID committed to improving reproductive health by expanding the contraceptive choices of women and men and by helping to prevent the transmission of HIV/AIDS and other sexually transmitted diseases. CONRAD is administered through the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA, with the main office located in Arlington, VA. www.conrad.org

Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention; and, gastrointestinal disorders. Biosyn, Inc is a wholly owned subsidiary of Cellegy Pharmaceuticals.

CellegesicTM (nitroglycerin ointment), branded Rectogesic® outside the United States, is approved and is being marketed in the United Kingdom by ProStrakan, for the treatment of pain associated with chronic anal fissures. A similar formulation of Rectogesic is currently being sold in Australia, New Zealand, Singapore and South Korea.

FortigelTM (testosterone gel), branded Tostrex® outside the United States, is marketed in Sweden for the treatment of male hypogonadism also by ProStrakan. Approvals of Rectogesic and Tostrex by the other member states of the European Union are being sought through the Mutual Recognition Procedure.


'"/>

Source:Rational PR


Related biology news :

1. Genomatix, AAAS ink agreement
2. A much-needed shot in the arm for HIV vaccine development
3. Clam embryo study shows pollutant mixture adversely affects nerve cell development
4. Zebrafish may hold key to understanding human nerve cell development
5. Scientists identify new model Of NK cell development
6. Influenza vaccine uses insect cells to speed development
7. Liposome finding implies electrical effect on cell development
8. Multi-purpose protein regulates new protein synthesis and immune cell development
9. Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development
10. Scientists find microRNAs regulate plant development
11. MicroRNA tweaks protein that controls early heart development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: